FEBS Open Bio

SJR Rank #5,594H-index: 58SJR: 0.919Best quartile: Q2Open AccessAPC: US$2,210Listed in DOAJ
Journal website: aims, scope and author guidelines
Publisher

John Wiley and Sons Inc

Country

United States

Type

journal

SJR by Edition

2022202500.250.50.751

Subject Categories

  • Biochemistry, Genetics and Molecular Biology (miscellaneous)Q2

Areas: Biochemistry, Genetics and Molecular Biology

Most published research topics

RNA modifications and cancerCancer-related molecular mechanisms researchMicroRNA in disease regulationRNA Research and SplicingRNA and protein synthesis mechanismsEpigenetics and DNA MethylationEnzyme Structure and FunctionAutophagy in Disease and TherapyCancer, Hypoxia, and MetabolismCircular RNAs in diseases

Source: OpenAlex

Publication Statistics

2025 Docs3-Year DocsCitable Docs0150300450600

Documents per Year

20222025050100150200

Detailed Information

ISSN

2211-5463

SJR Best Quartile

Q2

Region

Northern America

Citations per Document (2 years)

2.72

References per Document

51.84

Coverage

2011-2026

Scope

FEBS Open Bio is an online-only open access journal for the rapid publication of research articles in molecular and cellular life sciences in both health and disease. The journal's peer review process focuses on the technical soundness of papers, leaving the assessment of their impact and importance to the scientific community. FEBS Open Bio publishes experimental findings, critical analysis, methodological and technical innovations, and hypotheses. Novel or innovative work is encouraged, but papers describing sound science of a confirmatory nature in developing fields or extending knowledge of an important topic from one organism to another will also be considered. Articles originally submitted to other FEBS Press publications (FEBS Letters , The FEBS Journal and Molecular Oncology) can be transferred for consideration by FEBS Open Bio with their original reviewer reports, without the need to resubmit or reformat the manuscript.

Metrics from SCImago Journal Rank 2025. View on SCImago